Last reviewed · How we verify
RhPDGF-BB
At a glance
| Generic name | RhPDGF-BB |
|---|---|
| Also known as | ABSOLVE |
| Sponsor | Lynch Biologics LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction (PHASE2)
- Evaluating an rhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing (PHASE2)
- Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor (NA)
- Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis
- Fatty Liver and Pancreatic Steatosis
- Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences (NA)
- Reconstructive Therapy of Peri-implantitis with PDGF-BB (Gem-21) (PHASE4)
- A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RhPDGF-BB CI brief — competitive landscape report
- RhPDGF-BB updates RSS · CI watch RSS
- Lynch Biologics LLC portfolio CI